Chemoprevention of rat prostate carcinogenesis by 9-cis-retinoic acid.
A chemoprevention study was conducted to evaluate the activity of 9-cis-retinoic acid (9-cis-RA) as an inhibitor of prostate carcinogenesis in male Wistar-Unilever (HsdCpb:Wu) rats. After pretreatment with a sequential regimen of cyproterone acetate (50 mg/kg/day for 21 days) and testosterone propionate (100 mg/kg/day for 3 days), groups of 40 rats received a single i.v. injection of N-methyl-N-nitrosourea (MNU; 30 mg/kg body weight). Beginning 2 weeks after carcinogen administration, rats received chronic exposure to testosterone administered in s.c. implanted silastic capsules. The study was terminated at 13 months after MNU administration, and prostate cancer incidence was determined by histopathological evaluation of step sections of accessory sex glands. Continuous dietary administration of 9-cis-RA at 100 mg/kg diet or 50 mg/kg diet beginning 1 week before MNU administration reduced cancer incidence in the dorsolateral + anterior prostate from 65% in dietary controls to 18 and 20%, respectively (P < 0.001 for both comparisons). Similarly, these dose levels of 9-cis-RA reduced the incidence of cancer in all accessory sex glands from 79% in dietary controls to 48 and 33% (P < 0.01 for both comparisons), respectively. Chronic dietary administration of 9-cis-RA induced no gross or organ-specific toxicity in any animal and did not suppress group mean body weight gain. The potent anticarcinogenic activity of 9-cis-RA in the rat prostate, when considered with its apparent lack of toxicity in rodents, suggests that this and other ligands for the retinoid X receptor merit consideration for evaluation in clinical prostate cancer chemoprevention trials.
McCormick
D L
DL
Experimental Toxicology and Carcinogenesis Division, IIT Research Institute, Chicago, Illinois 60616, USA.
Rao
K V
KV
Steele
V E
VE
Lubet
R A
RA
Kelloff
G J
GJ
Bosland
M C
MC
D000077556:Alitretinoin; D000818:Animals; D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D002273:Carcinogens; D017373:Cyproterone Acetate; D004305:Dose-Response Relationship, Drug; D008297:Male; D008770:Methylnitrosourea; D009376:Neoplasms, Hormone-Dependent / Q000517:prevention & control*; D011471:Prostatic Neoplasms / Q000517:prevention & control*; D051381:Rats; D017208:Rats, Wistar; D013739:Testosterone; D014212:Tretinoin / Q000627:therapeutic use*